During 2014, Gilead's medicines helped more patients than ever before. Video Link Online Annual Review Read transcript
Exit Player
Loading the player ...


Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.

Liver Diseases   

Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.

Hematology / Oncology   

Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.


Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.

Inflammation / Respiratory   

We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.

Other Therapies   

Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.

Accessing Treatment for Chronic Hepatitis C   

Gilead has made it a priority to help ensure worldwide access to its first-in-class treatment for hepatitis C. Learn more.

Third Quarter 2015 Financial Results  

Access earnings press release, webcast link and slides for Gilead’s third quarter 2015 results. View materials.